# In Silico Development of Novel Quinazoline-Based EGFR Inhibitors via 3D-QSAR, Docking, ADMET, and Molecular Dynamics

## TL;DR

This study uses computer modeling to design new quinazoline compounds that could inhibit EGFR, a target in cancer treatment.

## Contribution

The study introduces new quinazoline-based EGFR inhibitors optimized via 3D-QSAR, docking, ADMET, and molecular dynamics simulations.

## Key findings

- 3D-QSAR models showed strong statistical performance with R² values of 0.981 (CoMFA) and 0.978 (CoMSIA).
- Compound Pred65 showed superior binding affinity and stability compared to Erlotinib in simulations.
- Eighteen new quinazoline derivatives were designed and evaluated for drug-like properties and ADMET profiles.

## Abstract

A library of thirty-one quinazoline derivatives was assessed as potential inhibitors of epidermal growth factor receptor kinase (EGFR) using 3D-QSAR methods, namely Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA). Training and test sets were generated by aligning the molecules to the lowest-energy conformer of the most active compound. The optimized models exhibited strong statistical performance, with R2 values of 0.981 (CoMFA) and 0.978 (CoMSIA), and cross-validation coefficients (Q2) of 0.645 and 0.729, respectively. External validation confirmed their predictive power, yielding R2 values of 0.929 and 0.909. Guided by these models, eighteen new quinazoline candidates were designed and evaluated for drug likeness and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties using in silico approaches. Molecular docking and molecular dynamics simulations highlighted the binding features and stability of these derivatives, with compound Pred65 demonstrating superior affinity and stability compared to Erlotinib. Collectively, the study provides valuable insights for the optimization of quinazoline scaffolds as EGFR inhibitors, supporting the development of promising anticancer leads.